Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05049850 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
A Phase 2 study, sponsored by Hansa Biopharma AB.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05049850 is a Phase 2 study that was terminated before completion, run by Hansa Biopharma AB. The registered enrollment target is 3 participants.
The verdict
NCT05049850, a Phase 2 study, was terminated before completion, sponsored by Hansa Biopharma AB.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether imlifidase in combination with bortezomib, belatacept, rituximab and IVIg can suppress donor specific antibodies (DSA) and the occurrence of antibody-mediated rejection (AMR) in highly sensitized patients with chronic kidney disease with a positive crossmatch towards their living donor during a period of 3 months from transplantation.
Interventions
- DRUG Imlifidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2024-05-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05049850
The ClinicalTrials.gov registry entry for NCT05049850 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hansa Biopharma AB, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imlifidase is the first listed.
NCT05049850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05049850 about?
NCT05049850 is a clinical study titled "A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation". The purpose of this study is to assess whether imlifidase in combination with bortezomib, belatacept, rituximab and IVIg can suppress donor specific antibodies (DSA) and the occurrence of antibody-mediated rejection (AMR) in highly sensitized patients with chronic kidney disease with a positive cros...
What is the current status of trial NCT05049850?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-12-16. Estimated completion is 2024-05-08.
What interventions are being tested in trial NCT05049850?
The interventions under investigation include: Imlifidase (DRUG).
Who is sponsoring clinical trial NCT05049850?
This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.